AbCellera Biologics
ABCL
138 hedge funds and large institutions have $552M invested in AbCellera Biologics in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 38 reducing their positions, and 50 closing their positions.
204% more call options, than puts
Call options by funds: $6.1M | Put options by funds: $2.01M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 38
1.73% less ownership
Funds ownership: 43.21% → 41.48% (-1.7%)
18% less funds holding
Funds holding: 169 → 138 (-31)
32% less capital invested
Capital invested by funds: $809M → $552M (-$257M)
62% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$26.2M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.05M |
| 3 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$1.36M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.28M |
| 5 |
DFCM
Dark Forest Capital Management
San Juan,
Puerto Rico
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.78M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.33M |
| 4 |
Renaissance Technologies
New York
|
-$5.14M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$3.98M |
ABCL Hedge Fund Activity: Q3 2023 in Review
138 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2023, worth a combined $552M — down 32% from $809M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of ABCL and 19 opened new positions — a net loss of 31 holders — while 38 trimmed existing stakes and 38 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $26.2M. The largest seller was Millennium Management, cutting an estimated $10.6M.
- 138 institutional investors held AbCellera Biologics (ABCL) as of Q3 2023, down from 169 in Q2 2023.
- Funds reported $552M of AbCellera Biologics stock for Q3 2023, down 32% quarter-over-quarter.
- 19 funds opened new AbCellera Biologics positions in Q3 2023 and 50 closed out, a net change of -31 holders.
- The largest AbCellera Biologics buyer in Q3 2023 was Baker Bros. Advisors, an estimated $26.2M added.
- The largest AbCellera Biologics seller in Q3 2023 was Millennium Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q3 2023.